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Abstract
Adenosine, an intercellular messenger that is a product of the metabolism of ATP, plays a major role in neuronal and vascular
responses of the retina to alterations in oxygen delivery. Significant changes in adenosine concentration have been measured in
the retina during both ischemia and during the subsequent reperfusion period which result in important, but complex, functional
effects. Adenosine A1 receptor stimulation produces a protective effect during ischemia, whereas overstimulation of the A2a
receptor has deleterious effects. The mechanisms underlying these findings have not been completely determined, but most likely
are the result of alterations in excitotoxicity, gene expression, and blood flow. Paradoxically, prolonged increases in adenosine
concentration may be injurious to the retina, a consequence of superoxide radical formation secondary to adenosine catabolism.
Adenosine is a critical mediator of blood flow changes in response to ischemia. It is a significant component of the retina’s
compensatory hyperemic response to ischemia, hypoxia, and hypoglycemia. Increasing endogenous adenosine concentrations may
be useful in ameliorating post-ischemic hypoperfusion. Overall, current evidence suggests that adenosine is a vital component of
the endogenous retinal response to substrate deprivation. Additionally, in vitro studies provide strong evidence that adenosine is
a mediator of the formation and effects of vascular endothelial growth factor, which in turn promotes neovascularization. Finally,
the ability of the retina to develop an ischemia-tolerant state by ischemic preconditioning is an intriguing phenomenon that reveals
yet another essential role for adenosine in the retina’s endogenous response to ischemia. The experimental results described in this
review suggest that continued investigation into the role of adenosine in the retina may lead to important clinical applications for
adenosine-based therapies that could decrease the incidence of retinal damage in ischemic vasculopathies such as diabetes,
glaucoma, and retinal vascular occlusion. © 1999 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Adenosine, a purine nucleoside product of the
metabolism of high-energy phosphates, is a significant
intercellular mediator in the central nervous system, a
role first recognized over 40 years ago (see Williams &
Burnstock, 1997, for review). Important roles in which
adenosine serves in a regulatory or modulatory capacity
include: neurotransmission, blood flow, inflammation,
pain, and the endogenous response to ischemia (Phillis,
1989; Cronstein, 1994; Rudolphi & Schubert, 1997).
Three major receptor classes for adenosine have been
characterized: these are designated as A1, A2, and A3
adenosine receptors (Jacobson, Galen & Williams,
1992). The receptors are G-protein linked, and subserve
a variety of different effects upon adenylyl cyclase, ion
channels, and phospholipase C (Table 1).
A growing body of evidence indicates that adenosine
is an important intercellular mediator in the retina. It is
widely, although heterogeneously, distributed through-
out the retina of various species (Blazynski & Perez,
1991). A1 receptor binding sites occur mostly in the
inner retina, whereas A2 receptor binding sites are
predominantly found in the outer retina. The highest
adenosine immunoreactivity is present in the ganglion
cell, inner plexiform, and inner nuclear layers (Braas,
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Zarbin & Snyder, 1987). This distribution of adenosine
suggests that it is well positioned to serve as a mediator
of important physiological and pathophysiological pro-
cesses in the retina. Because of its diverse roles in
neurotransmission and the control of tissue blood flow,
adenosine appears to be of particular importance in the
pathophysiology of ischemic disease, but much remains
to be learned about its ubiquitous effects. Results of
recent experiments from several laboratories, including
our own, are confirming the physiologic and patho-
physiologic significance of adenosine in animal models
of retinal vascular disease, which is related to adeno-
sine’s ability to regulate and influence tissue perfusion
and metabolism. This review summarizes our current
understanding of the role of adenosine in normal re-
tinal function, and its unique roles in the pathophysiol-
ogy of ischemic retinal vascular disease.
2. Retinal vascular disease: pathophysiology
Most cases of visual loss and blindness in the United
States are caused by diseases that are ultimately sec-
ondary to retinal ischemia. Retinal ischemia can occur
from direct decreases in blood supply as a result of
retinal arterial or venous occlusion, or from acute and
chronic tissue hypoxia. Glaucoma, atherosclerosis, and
the ocular complications of systemic disorders such as
diabetes mellitus also lead to retinal ischemia. The
neovascularization that follows is a common feature of
many chronic eye diseases and is the major cause of
blindness in the world (Miller, Adamis & Aiello, 1997).
This neovascularization is thought to occur secondary
to ischemia- or hypoxia-induced stimulation of dif-
fusible growth factors (e.g., vascular endothelial growth
factor, VEGF) which promote neovascularization of
the retina and optic nerve head. However, the pathways
responsible for increased production of these factors in
response to acute or chronic hypoxia:ischemia are in-
completely understood. Depending on the character of
the ischemic stimulus, the purine nucleoside adenosine
appears to serve at least two key roles: as an intercellu-
lar signaling factor promoting the neovascularization
process after chronic hypoxia or ischemia, and as an
endogenous protective factor capable of protecting the
retina from acute ischemia.
3. Biochemistry and gene expression in retinal ischemic
disorders
Depriving cells in the central nervous system of oxy-
gen results in a number of critical biochemical alter-
ations. Among these are the breakdown of ATP to
adenosine, and the enhanced release from inside the cell
of excitatory amino acids (glutamate, aspartate) which
bind to specific receptors (Choi, 1995), initiating a
complex series of injurious reactions known as excito-
toxicity. Strong support for a parallel mechanism in the
retina is suggested by a number of different studies.
Elevated extracellular glutamate concentrations are
found in the in vivo rat retina during ischemia
(Louzada, Dias, Santos, Lachat, Bradford & Coutinho-
Netto, 1992) and in the vitreous of monkeys and hu-
mans with glaucoma (Dreyer, Zurakowski, Schumer,
Podos & Lipton, 1996). Moreover, glutamate receptor
antagonists attenuate ischemic injury in vitro and in
vivo (Yoon & Marmor, 1989; Zeevalk & Nicklas, 1990;
Mosinger, Price, Bai, Xiao, Wozniak & Olney, 1991).
However, treatment with excitatory amino acid an-
tagonists may not be sufficient to effectively interrupt
the excitotoxic pathway (Mosinger, Price, Bai, Xiao,
Wozniak & Olney, 1991; Lipton & Rosenberg, 1994;
Chen, Harris, Brown, Howe, Surmeier & Reiner, 1995;
Dreyer et al., 1996). In fact, ischemia triggers multiple
biochemical cascades, including alterations in genetic
expression, that may injure or, alternately, protect re-
tinal cells. Therefore, examination of additional non-
glutamatergic mechanisms that may be involved in the
pathophysiology of retinal ischemic damage has as-
sumed a growing interest and significance.
In the brain, ischemia was found to increase the
expression of immediate early gene products, e.g., c-fos,
heat shock protein, and amyloid precursor protein,
among others (Atkins, Liu & Hsu, 1996; Koistinaho &
Hokfelt, 1997). Ischemia-induced alterations in gene
expression have also been documented in the retina.
Specifically, increased activity of the tyrosine kinase
pathway was found in the rat retina after ischemia and
reperfusion. This activation of signal proteins could
play a role in ischemia-induced cellular proliferation
(Hayashi, Koroma, Imai & de Juan, 1996), although it
is not yet clear which of these mechanisms are injurious
or represent possibly an endogenous protective re-
sponse to ischemia. Additionally, mRNA for VEGF
was increased in retinal capillary endothelial cells and
pericytes exposed to hypoxia, suggesting a pathogenic
Table 1
Receptor-effective couplinga
Receptor EffectorG-protein
Gia123A1AR ¡Adenylyl cyclase
 Phospholipase CGqa?
 K channelsGqa?
A2aAR Gsa  Adenylyl cyclase
A2b  Adenylyl cyclaseGsa
 Ca2 channels
Gia23 ¡Adenylyl cyclaseA3AR
 Phospholipase C
der\ Phospholipase C
a Stiles (1997).
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Fig. 1. Immunochemical staining for adenosine in rat (A) and guinea pig (B) retinae, showing the distribution of adenosine in the retina. Retinal
8 mm thick paraffin sections were stained using specific adenosine antisera. Symbols: gc, ganglion cell layer; ip, inner plexiform layer; in, inner
nuclear layer; op, outer plexiform layer; on, outer nuclear layer; os, outer segments of the photoreceptor cell layer. Reprinted with permission from
Braas et al. (1987).
mechanism for vasoproliferative diseases (Takagi, King,
Ferrara & Aiello, 1996a) (see Section 9.3). These and
related findings support the theory that changes in gene
expression play a significant role in the pathogenesis of
ischemic disorders in the retina.
Presently, it remains largely unknown which signals
initiate changes in gene expression following ischemia.
However, adenosine may serve this role under some
conditions (Asaoka, Nakamura, Yoshida & Nishizuka,
1992; Kontny, Kvanta & Fredholm, 1992; Kvanta &
Fredholm, 1993). For example, in brain it is theorized
that adenosine may stimulate the release of neuro-
trophic factors such as nerve growth factor, which
could be neuroprotective (Rudolphi & Schubert, 1997).
Adenosine stimulated the production of VEGF in reti-
nal endothelial cells in vitro (Takagi, King, Robinson,
Ferrara & Aiello, 1996b). Our most recent studies
indicate that adenosine is essential for the production
of the endogenous retinal protective response caused by
ischemic preconditioning (IPC), i.e., the induction of
retinal tolerance to ischemia that occurs following a
brief, non-damaging ischemic insult (Roth, Li, Rosen-
baum, Gupta, Goldstein, Maxwell et al., 1998). IPC
protection was also shown to require de novo protein
synthesis. These sets of findings suggest that adenosine
may be a critical signal in the control of gene expres-
sion after retinal ischemia (Li & Roth, in press).
4. Adenosine localization in the retina
During resting conditions, endogenous purines in the
retina exist primarily in the form of ATP (70%) with
only 2% existing as adenosine (Perez, Ehinger, Lind-
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Fig. 2. Low power photomicrographs of retinal sections after in situ hybridization with antisense oligonucleotide probes to the adenosine A1 and
A2a receptors, demonstrating the distribution of the receptor mRNA in the rat retina. Left panel is a dark field photomicrograph of A1 receptor
mRNA distribution. The right panel is a bright field photomicrograph of A2a receptor mRNA distribution. Symbols: gc, ganglion cell layer; in,
inner nuclear layer; on, outer nuclear layer; ch, choriocapillaris. The left panel shows that A1 receptor mRNA is present in the ganglion cell, inner
nuclear, and outer nuclear layers. The right panel indicates that A2a receptors are found in the inner and outer retina. Adapted with permission
of Academic Press, from Kvanta et al. (1997).
strom & Fredholm, 1986). Endogenous adenosine is
widely distributed within the retina, and its localization
shows similarities in distribution in a variety of species.
In the rat, guinea pig (Fig. 1), monkey, and human
retinae, nearly all of the adenosine immunoreactivity
was found in the ganglion cell, inner plexiform, and
inner nuclear layers (Braas et al., 1987; Blazynski,
Mosinger & Cohen, 1989a). A small population of
photoreceptor cells contained adenosine (Braas et al.,
1987). In the cat, adenosine was autoradiographically
localized to the ganglion cell and inner nuclear layers,
particularly over cell bodies in the vitreal half, likely
representing amacrine cells (Blazynski, Cohen, Fruh &
Niemeyer, 1989b).
Adenosine receptors are localized generally to many
of the same retinal layers as endogenous adenosine.
Autoradiographic studies in rat retina using the A1
selective ligands L-[3H]-phenylisopropyladenosine (PIA)
and [125I]-hydroxyphenylisopropyladenosine localized
the A1 receptor to the nerve fiber, ganglion cell, and
inner plexiform layer as well as to the inner portion of
the inner nuclear layer (Braas et al., 1987). The monkey
retina showed A1 receptors distributed from the nerve
fiber to the outer plexiform layers, while the human
retina showed widespread binding of the A1 receptor
ligand throughout the entire retina. However, A1 recep-
tors seemed to be most plentiful in the nerve fiber layer
of the human inner retina (Braas et al., 1987). Labeling
of rabbit and mouse retinas with tritiated PIA, cy-
clopentyladenosine (CPA), and N-ethylcarboxami-
doadenosine (NECA) revealed that A1 receptors were
limited to the inner retina, most notably over the inner
plexiform layer, whereas A2 receptors were localized to
the retinal pigment epithelium (RPE) and both the
outer and inner segments of photoreceptors (Blazynski
& McIntosh, 1992). Adenylate cyclase assays and radi-
oligand binding studies on bovine retina preparations
using NECA in the presence of the A1 selective agonist
CPA revealed two classes of A2 binding sites: a high
affinity A2a receptor and a low affinity A2b receptor.
Adenosine receptors were recently localized in the rat
eye by in situ hybridization with 35S-labeled sense and
antisense probes (Kvanta, Seregard, Sejersen, Kull &
Fredholm, 1997). In general, for the A1 receptor, there
was agreement between localization of the receptor
transcript and the translational product described in
earlier studies. A1 mRNA was found particularly in the
ganglion cells, some of the inner nuclear cells, and in
the ciliary bodies (Fig. 2). No A1 mRNA was found in
the outer nuclear layer. A2a mRNA was found in the
ganglion cell, inner nuclear, and outer nuclear layers,
and in the choriocapillaris (Fig. 2). While the A3 recep-
tor has been described in other tissues including testis,
kidney, lung, heart, and, to a lesser degree, brain, no
significant expression of A3 mRNA was found in rat
eye (Linden, Taylor, Robeva, Tucker, Stehle, Rivkees et
al., 1993). While 3H-NECA-binding studies localized
A2 receptors to human RPE (Friedman, Hackett, Lin-
den & Campochiaro, 1989), no A2a or A2b mRNA
could be found in RPE (Kvanta et al., 1997). However,
human RPE cells in culture accumulated cyclic AMP in
response to the non-selective A2 adenosine agonist
NECA, suggesting the presence of adenosine A2 recep-
tors on these cells (Friedman et al., 1989). Moreover,
since PIA and CPA, both relatively selective A1 recep-
tor agonists, had no effect on isoproterenol-stimulated
cyclic AMP levels in this tissue, the latter authors
concluded that RPE cells do not contain A1 receptors
typically linked to decreases in cyclic AMP formation.
Divergent findings between studies using the subtype-
specific antisense probes versus autoradiography may
be partly explained by non-specific binding of 3H-
NECA to the A1, A2a, and A2b receptors. Alterna-
tively, the results of in situ hybridization for mRNA
may differ because the translated receptor product is
translocated, and therefore localization of the mRNA
may differ from that of the receptor itself.
In summary, adenosine’s wide distribution through-
out the retina has been documented in a diverse num-
ber of species. Found predominantly in the inner retina,
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it is also present in the RPE and in photoreceptors. The
A1 receptor occurs mostly within the inner retina, while
the A2 predominates within the outer retina. There is,
as yet, no evidence for A3 receptor activity in the
retina. The localization of adenosine receptor mRNA
transcripts generally correlates well with autoradio-
graphic localization of the A1, but not the A2 recep-
tors. This widespread distribution of adenosine and its
receptors suggests that adenosine is well positioned to
serve as a mediator of important physiological and
pathophysiological processes in the retina.
5. Molecular biology and pharmacology of adenosine
receptors
The physiological actions of adenosine result from its
binding to specific receptors, leading to the activation
of signal transduction systems. All of the adenosine
receptors have been cloned, although to date, the ge-
nomic structure is available only for the A1 receptor.
The adenosine receptor systems interact with a wide
variety of G-proteins, including Gi, Go, Gq, and Gs
(Table 1).
The A1 receptor was cloned from rat, human,
bovine, and rabbit. The clones and the expressed recep-
tor protein are similar between the various species. The
A1 receptor is about 326 amino acids, or 36–37 kDa.
Mutations in His-274 and His-251 result in loss of
agonist and antagonist binding. Multiple regions are
responsible for the binding of receptor agonists and
antagonists; using chimeric receptor constructs,
transmembrane domains 5, 6, and 7 were shown to be
important for the binding of agonists and antagonists
(Stiles, 1997). In the brain, A1 receptors couple to the
G-proteins Gi and Gs and inhibit adenylyl cyclase. The
A1 receptor is primarily involved in the inhibitory
actions of adenosine. These include depression of the
membrane potential (via increased K and Cl con-
ductance), decreased calcium influx, and depression of
neurotransmitter release, including, e.g., glutamate, and
dopamine (Crosson, DeBenedetto & Gidday, 1994).
These effects result in decreased neuronal excitability
and metabolism (Schubert, Rudolphi, Fredholm &
Nakamura, 1994; Rudolphi & Schubert, 1997), and can
be considered neuroprotective in the setting of tissue
ischemia.
The A2a receptor was cloned from a canine, rat, and
human. It is 410–412 amino acids in size, or about 45
kDa, comparable in size to the A1 receptor (Stiles,
1997). Mutations in similar regions to those of the A1
receptor also lead to loss of agonist and antagonist
binding. However, there are at present few specific
ligands for studying the structure of the A2a receptor.
A2a (high affinity) and A2b (low affinity) receptors are
Gs-coupled and are traditionally thought to activate
adenylyl cyclase (Schubert et al., 1994). Adenosine re-
laxes vascular smooth muscle by an A2-receptor-medi-
ated mechanism, thereby promoting increases in tissue
perfusion. Recent evidence indicates that, in retina,
these vasodilatory effects of adenosine are mediated by
A2 receptors linked in a unique way to KATP channels
(Gidday, Maceren, Shah, Meier & Zhu, 1996). A2
receptors may also be important in adenosine’s neuro-
modulatory effects that occur in concert with A1 recep-
tors (Sebastiao & Ribeiro, 1996). There is also evidence
from retinal slices that adenosine promotes glycogeno-
lysis via an A2 receptor on Muller cells (Osborne,
1989). This would represent yet another way adenosine
promotes an increase in the supply:demand ratio for
metabolic substrates in the retina. Stimulation of the
A2a receptor decreases superoxide release from acti-
vated neutrophils and inhibits platelet aggregation
(Cronstein, 1994), which are documented anti-inflam-
matory actions in vitro, not yet demonstrated to be of
importance in the retinal response to ischemia. The role
of the A2b receptor has not yet been clearly established.
The A3 receptor was cloned from human, rat, and
sheep. It is about 320 amino acids in size, and 40–50%
of these are identical to the structures of the A1 and A2
receptors. This receptor has low affinity for alkylxan-
thine antagonists like theophylline and caffeine, which
are classic antagonists at the A1 and A2 receptors.
Recently, the agonist IB-MECA was developed which
binds to the A3 receptor, although not specifically
(Linden, 1994). Specific antagonists have also recently
been described (Jacobson, 1998). The A3 receptor in-
hibits adenylyl cyclase and activates phospholipase C
(Table 1) (Linden, 1994). Stimulation of the A3 recep-
tor also enhances Ca2 mobilization and inhibits TNF-
a (Linden et al., 1993; Linden, 1994). Considerably
higher adenosine concentrations than would be active
at A1 and A2 receptors, likely generated during is-
chemia, are required to activate the A3 receptor (Ki1
mM versus 10 and 30 nM for A1 and A2a in the rat,
respectively). In the cerebral cortex in gerbils, the acute
administration of an A3 receptor antagonist or the
chronic administration of an A3 receptor agonist pro-
tected against damage from global ischemia, suggesting
possible therapeutic approaches involving the A3 recep-
tor (Jacobson, 1998). However, further studies are nec-
essary to precisely define the role of the A3 receptor in
ischemic retina.
6. Adenosine metabolism
While adenosine formation and metabolism have
been studied in detail in organs such as skeletal muscle,
brain, and heart, relatively little data currently exist
concerning these processes in the retina. Ganglion and
inner nuclear layer cells accumulated adenosine, pro-
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Fig. 3. Pathways for adenosine production and metabolism. Reproduced with the permission of Oxford Press, Inc., from Roth et al. (1997a).
cesses blocked by the purine nucleoside transport in-
hibitor nitrobenzylthioinosine (NBTI) (Blazynski,
1991). From studies in other organs, it has been found
that adenosine may be formed both intra- and extracel-
lularly (Fig. 3), but intracellular metabolism of ATP by
the action of 5%-nucleotidase, and metabolism of S-
adenosyl-homocysteine by a hydrolase enzyme (Zhang,
Franklin & Murray, 1993) predominate. This latter
pathway contributes significantly to adenosine forma-
tion in the heart (Deussen, Lloyd & Schrader, 1989)
and during ischemic conditions in the brain (Latini,
Corsi, Pedata & Pepeu, 1996). Once formed, intracellu-
lar adenosine must be transported out of the cell in
order to exert its effects upon cell surface receptors.
Adenosine transport out of the cell is facilitated and
bidirectional (Schubert et al., 1994). Extracellular
adenosine is believed to originate from membrane
bound 5%-nucleotidase (ecto-5%-N)-catalyzed breakdown
of 5%-AMP. This mechanism of adenosine formation
can be differentiated from intracellular adenosine for-
mation using specific antibodies to and inhibitors of
ecto-5%-N (Smolenski, Kochan, McDouall, Page, Sey-
mour & Yacoub, 1994). Since AMP is formed from the
breakdown of ATP, adenosine formation is closely
linked to cellular energy state, and can thus serve as a
signal to increase the energy supply:demand balance
primarily by affecting cellular metabolic rate and tissue
perfusion.
Adenosine’s metabolites may also have significant
physiological and pathological effects. The levels of
adenosine available for these effects are determined by
a number of factors, which include its rate of produc-
tion, transport, and metabolism. Degradation of
adenosine is catalyzed by adenosine deaminase (ADA)
or adenosine kinase (AK); both are believed to be
located primarily in the cytoplasm (Sciotti & van
Wylen, 1993; Geiger, Parkinson & Kowaluk, 1997).
ADA (EC 3.5.4.4) is a 36 kDa protein that forms a 280
kDa polypeptide via its binding to ADA-binding
proteins (Geiger, Padua & Nagy, 1991). ADA catalyzes
the formation of inosine from adenosine. It is heteroge-
neously distributed among tissues, with its activity
highest during development. AK (EC 2.7.1.20) is a
monomeric protein of molecular weight 38–56 kDa,
and is widely distributed throughout the body. It cata-
lyzes the phosphorylation of adenosine to 5%-AMP. This
reaction is inhibited by the specific inhibitor 5-iodotu-
bercidin (Phillis & Smith-Barbour, 1993). AK cDNA
has been recently cloned (Spychala, Datta, Taka-
bayashi, Datta, Fox, Gribbin et al., 1996). Since
adenosine can inhibit AK when the intracellular con-
centration of adenosine is only slightly greater than the
apparent Km for the enzyme, it has been proposed that
two adenosine-binding sites exist on AK. One is a
high-affinity catalytic site, the other a low-affinity in-
hibitory site that may require the binding of Mg2.
The kinetic mechanisms of AK require further elucida-
tion (Geiger et al., 1997).
Five types of adenosine transporters exist, classified
according to their sensitivity to the transport inhibitor
NBTI. Multiple transport processes may coexist in the
same cell. Some of these transport processes are Na-
dependent. Adenosine transporters may favor influx or
efflux and are thought to be bidirectional (Geiger et al.,
1997). Following adenosine’s conversion to inosine, the
final catabolic steps involve the enzymes xanthine dehy-
drogenase (XDH, EC 1.1.1.204) or oxidase (XO, EC
1.1.3.22) (Amaya, Yamazaki, Sato, Noda, Nishino &
Nishino, 1990). Xanthine dehydrogenase catalyzes the
oxidation of hypoxanthine to xanthine and of xanthine
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to uric acid, resulting also in the reduction of NAD to
NADH. XDH is a molybdenum iron-sulfur flavin hy-
drolase that exists as a dimer with a molecular weight
of approximately 150 kDa (Poss, Huecksteadt, Panus,
Freeman & Hoidal, 1996). XDH may be converted
through reversible sulfhydryl oxidation or irreversible
proteolytic modification to the oxygen-dependent en-
zyme XO. XO generates superoxide radical (O2) and
hydrogen peroxide (H2O2), which are damaging to cells.
Endothelial cells are key sources of XO (Terada, Will-
ingham, Rosandich, Leff, Kindt and Repine, 1991;
Terada, Guidot, Leff, Willingham, Hanley, Piermattei
et al., 1992), the formation and activity of which is
stimulated by ischemia and reperfusion.
7. Measurement of retinal adenosine concentration
The accurate detection of adenosine is important in
experiments that examine the impact of alterations in
adenosine concentration on physiological parameters
such as blood flow or electrophysiological function.
One of the major difficulties in analyzing tissue purine
concentrations is that samples must be taken rapidly
enough to ensure that metabolic enzyme activity does
not continue during tissue processing and thus falsely
alter the adenosine concentration, either by continued
adenosine formation or metabolism (Fredholm, 1987).
Frozen tongs (Berne, Rubio & Curnish, 1974) or in situ
freezing (Rehncrona, Siesjo & Westerberg, 1978) were
used to sample cerebral cortical tissue, but artifacts due
to tissue damage may increase adenosine concentration
(Winn, Rubio & Berne, 1981). The freeze-blow method
(Winn et al., 1981) allowed accurate sampling of
adenosine concentration in deeper portions of the cere-
bral cortex. Another technique measures tissue
adenosine concentration after subjecting animals to
rapid microwave irradiation (Phillis & O’Regan, 1996).
This method is highly effective, but requires a costly
apparatus not universally available. The disadvantage
of all tissue sampling methods is that intracellular and
extracellular adenosine concentrations cannot be differ-
entiated, but relative changes in total adenosine concen-
tration may be measured.
Microdialysis or sampling from cortical cup prepara-
tions has been used to estimate cerebral extracellular
adenosine concentration (Headrick, Bendall, Faden &
Vink, 1994; Phillis, Smith-Barbour, O’Regan & Perkins,
1994), but neither of these methods seems practical for
adenosine measurement in the retina. Recently, concen-
trations of adenosine and its metabolites were effec-
tively measured using high performance liquid
chromatography (HPLC) from the intact in vivo rat
retina (Roth, Osinski, Park, Ostwald & Moshfeghi,
1996). Quantitative, accurate, and reproducible mea-
surements of the small concentrations were made possi-
ble through the use of internal standards. This
technique requires in situ freezing of the eyes, after
which the retina is separated from the other eye tissues
and processed. Unlike in brain, in situ freezing is highly
effective for the retina because of the small size of the
eye and the presence of the aqueous vitreous in immedi-
ate proximity to the retina. The main disadvantages are
that only one measurement can be performed per ani-
mal, and adenosine content of the retina and choroid
cannot be analyzed separately. In addition, both extra-
cellular and intracellular adenosine are measured. How-
ever, the vitreous may be sampled and analyzed to
provide data on concentrations of purine metabolites in
extracellular fluid. These measurements have been per-
formed in the in vivo intact rat retina subjected to
ischemia and reperfusion for varying periods of time,
and the time course of changes in purine concentration
during and immediately after ischemia has been eluci-
dated (Roth, Park, Sikorski, Osinski & Chan, 1997a;
Roth, Rosenbaum, Osinski, Park, Toledano, Li et al.,
1997b).
8. Changes in adenosine concentration during ischemia
and reperfusion
We examined the time course of changes in the
concentration of adenosine and its metabolites in the
rat retina during ischemia-reperfusion using HPLC
(Roth et al., 1997a,b). The changes in purine concentra-
tion during ischemia followed a time course consistent
with the formation and subsequent metabolism of
adenosine, i.e., significant increases in adenosine con-
centration were recorded within 5 min after the onset of
ischemia. In the vitreous, the concentrations of inosine
and hypoxanthine were not elevated until 60 min of
ischemia, probably reflecting a slow diffusion of these
substances from the retina into the overlying vitreous
(Roth et al., 1997b). All increases in purine concentra-
tion lasted through 120 min of ischemia, the longest
timepoint we tested. Increases in adenosine concentra-
tion during ischemia plateaued after 30 min, suggesting
that the production of adenosine is a fairly short-lived
response to ischemia. Conversely, the ongoing increase
in the concentrations of adenosine metabolites occur-
ring after 30 min of continuous ischemia indicate that
prolonged ischemia activates enzymatic pathways cata-
lyzing the conversion of adenosine to several down-
stream metabolites.
The concentrations of adenosine and its metabolites
in the rat retina-choroid were also measured during
reperfusion following both short (10 min) and long (60
min) periods of ischemia (Roth et al., 1997a). Changes
in the concentration of adenosine and its metabolites
were approximately 4-fold greater in magnitude follow-
ing the more prolonged ischemia. In the latter instance,
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adenosine, inosine, and hypoxanthine concentrations
remained elevated through the initial 30 min of reperfu-
sion. The peak in xanthine concentration was delayed
(30 min) in comparison to adenosine (5 and 10 min),
and elevations in xanthine levels were sustained to 60
min of reperfusion.
In summary, these data indicate that retinal ischemia
results in a rapid increase in adenosine and its purine
metabolites, and that the concentrations achieved dur-
ing ischemia are proportional to the duration of is-
chemia. The increase in adenosine concentration that
occurs during early reperfusion after prolonged is-
chemia correlates well with the finding that adenosine
mediates post-ischemic hyperemia (Ostwald, Park,
Toledano & Roth, 1997). During prolonged ischemia,
and in the reperfusion period after ischemia, delayed
increases in adenosine metabolites may paradoxically
damage the retina as a result of superoxide radical
formation from the XO-mediated conversion of hypox-
anthine to xanthine and of xanthine to uric acid (Roth
et al., 1997a).
9. Functional effects of adenosine in the retina
9.1. In 6i6o effects of A1 and A2 receptor stimulation
in retinal ischemia
Recent studies have shown that adenosine plays an
extremely important functional role in the retina’s re-
sponse to ischemia. In rats subjected to retinal ischemia
by elevation of intraocular pressure, intravitreal injec-
tion of adenosine deaminase nearly eliminated the
postischemic recovery of the electroretinogram (ERG)
b-wave. In contrast, the adenosine deaminase inhibitor
erythro-9-(2hydroxy-3-nonyl)adenine hydrochloride
(EHNA) significantly enhanced the rate of b-wave re-
covery (Larsen & Osborne, 1996), and prevented is-
chemia-induced thinning of retinal cell layers (Fig. 4).
These authors suggested that the protective effect of
EHNA was mediated via adenosine’s binding to the A1
receptor, because systemic injection of the A1 receptor
agonist R-PIA also enhanced recovery. The 45 min of
ischemia used in this study was not a severe ischemia,
because of inconsistent histological damage to the
retina and a 54% recovery of the ERG b-wave by 3
days after ischemia. Nonetheless, the results suggest
that increases in adenosine concentration during and
immediately after ischemia (Roth et al., 1997a,b) may
serve in an endogenous protective capacity.
However, this conclusion may actually depend on the
relative stimulation of different adenosine receptors and
the severity of ischemia. To examine the impact of
severity of ischemia, rats were subjected to ischemia for
5, 30, or 60 min by ligation of the central retinal artery;
the recovery of the ERG a- and b-waves was followed
for up to 7 days later, and retinas were examined
histologically on the 7th post-ischemic day. Following 5
min of ischemia, there was complete recovery of the a-
and b-waves and no evidence of histological damage. In
contrast, after 60 min of ischemia there was B15%
recovery of electrical function, and at least a 50%
reduction in retinal cell layer thickness and cell counts
(Roth et al., 1998). However, 30 min of ischemia re-
sulted in injury of intermediate severity, leading to
45–50% recovery of the a- and b-waves, but no histo-
logical damage. Thus, the effects of adenosine receptor
blockade in the rat model could be examined under
conditions of differing ischemic durations (Li, Rosen-
baum, Jennings, Maxwell & Roth, 1999).
Using electrophysiological and histological ap-
proaches, we studied the roles of the A1 and A2a
receptors in this graded ischemia model (Li et al.,
1999). The A1 receptor selective antagonist DPCPX
given prior to 5 or 30 min of ischemia decreased the
recovery of the a- and b-waves by \50% within the
first 2 h after ischemia ended, with the effect persisting
up to 7 days later in the rats subjected to 30 min of
ischemia. DPCPX given prior to 60 min of ischemia
had no effect upon a- and b-wave recovery, and there
were no significant differences in histological findings in
vehicle-versus DPCPX-injected rats subjected to severe
(60 min) ischemia. The A2a antagonist CSC, given
prior to 5 min of ischemia, decreased the recovery of
the a- and b-waves in the first 120 min after ischemia,
but by day 1 after ischemia there was no difference
from vehicle-injected animals. CSC given prior to 30 or
60 min of ischemia resulted in nearly complete post-is-
Fig. 4. Treatment of rat retina with the adenosine A1 receptor agonist
R-N6-(2-phenylisopropyl) adenosine (R-PIA) or the adenosine deami-
nase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride
(EHNA) prior to ischemia attenuates the loss of thickness of the
inner plexiform and inner nuclear layers. Retinas were sectioned 1 mm
thick, and stained with toluidine blue-Azure II, then examined using
light microscopy. Results are expressed as mean9S.E.M. ** PB
0.01, and *PB0.05 in comparison to the control, non-ischemic
retinas. Redrawn with permission of the Association for Research in
Vision and Ophthalmology from Larsen and Osborne (1996).
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Fig. 5. Representative photomicrographs (100 ) demonstrating the effects on retinal structure of antagonism of adenosine A1 or A2a receptors
prior to 60 min of ischemia. Systemic administration of CSC 1 mg:kg prior to 60 min of ischemia in rats resulted in nearly complete preservation
of retinal structure compared to that present in vehicle-treated animals. In rats treated with DPCPX 4.5 mg:kg prior to ischemia there was greater
loss of the ganglion cells compared to vehicle treated rats. Retinas were collected from rats 7 days after ischemia, sectioned 1 mm thick, and stained
with toluidine blue. Symbols: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer.
Reproduced with permission of Acedemic Press, Inc., from Li et al. (1999).
chemic recovery up to 7 days after ischemia. Moreover,
retinas treated with CSC prior to 60 min of ischemia
demonstrated profound structural protection in com-
parison to vehicle-treated controls (Fig. 5). Neither A1
nor A2a receptor blockade produced any significant
effect upon the non-ischemic retina.
It appears from these data that activation of A1
adenosine receptors during and following retinal is-
chemia promotes neuroprotective effects, whereas acti-
vation of A2a adenosine receptors promotes ischemic
injury. These results are in agreement with previous
studies in cerebral ischemia (Phillis, 1995) wherein ex-
ogenous administration of A1 receptor agonists en-
hanced recovery after short-term ischemia. Why the A1
receptor affords protection only after brief periods of
ischemia, but not when ischemia is more prolonged,
could be the result of a down-regulation of the A1
receptor that occurs after more extended periods of
ischemia (Lee, Tetzlaff & Kreutzberg, 1986; Rudolphi
& Schubert, 1997). Conversely, post-ischemic upregula-
tion of the A2a receptor, possibly during the time of A1
down-regulation, has been suggested from studies of
cerebral ischemia in the gerbil (von Lubitz, Carter,
Beenhakker, Lin & Jacobson, 1995). Precisely how A2a
receptor blockade might be protective is not known.
Among the possible mechanisms are alterations in
blood flow (Gidday & Park, 1993a), decreased release
of excitatory amino acids (Sebastiao & Ribeiro, 1996),
or changes in expression of other intercellular signalling
molecules such as VEGF (Takagi et al., 1996a).
In summary, these studies show that the involvement
of adenosine in retinal ischemia is not a simple matter
of increases in adenosine concentration being acutely
protective; rather, they suggest a complex interaction of
adenosine effects at different receptor subtypes. It ap-
pears that enhancing A1 receptor activity, and decreas-
ing A2a receptor activity, are protective. The
mechanisms activated by adenosine’s stimulation of
each receptor subtype have not yet been identified.
9.2. Significance of adenosine metabolism
As discussed above, increases in the concentrations of
adenosine may not necessarily protect the retina from
ischemic injury. In addition to the differing effects of
A1 and A2 receptor stimulation, of considerable impor-
tance in retinal ischemic outcome are the functional
consequences of the formation of adenosine metabo-
lites. These metabolites could be injurious to the retina,
since the metabolism of hypoxanthine and xanthine
may increase oxidative stress. The impact of adenosine
metabolism on the outcome after retinal ischemia has
been examined by pharmacological inhibition of these
metabolic pathways. Treatment of isolated perfused cat
eyes with allopurinol, an inhibitor of XO, reduced the
damage that resulted from ischemia (Peachey, Green &
Ripps, 1993).
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Post-ischemic electroretinographic recovery was also
significantly increased in this model following allopuri-
nol pretreatment. These results suggest that during
reoxygenation, the action of XO produces superoxide
radical which impairs functional recovery of the retina.
However, allopurinol at the doses used in this study
could have served as a free radical-scavenger itself
(Augustin, Boker, Blumenroder, Lutz & Spitznas,
1994). Thus, this beneficial effect may be a result of a
combination of XO inhibition as well as the direct
quenching of superoxide radical.
The effect of inhibition of XO in the intact rat retina
subjected to ischemia for 60 min was recently studied
(Roth et al., 1997a). The allopurinol metabolite oxy-
purinol (40–80 mg:kg), another inhibitor of XO,
caused a dose-dependent improvement in recovery of
the electroretinogram b-wave in the rat up to 7 days
following 60 min of ischemia. Taken together with the
significant, time-dependent increases in hypoxanthine
and xanthine concentrations during ischemia and reper-
fusion (Roth et al., 1997a), these results indicate that
the retina can be damaged by the formation of
adenosine metabolites, and that treatment of ischemic
disorders in the retina might be amenable to interven-
tion with xanthine oxidase inhibition, provided effective
post-ischemic treatment with xanthine oxidase in-
hibitors can be demonstrated experimentally. The cell
types producing superoxide via the XO pathways, and
those protected by XO inhibition have not yet been
identified.
9.3. Adenosine in diabetic and other ischemic
retinopathies
Chronic retinal ischemia is a common mechanism
that leads to blindness in conditions such as diabetic
retinopathy and retinopathy of prematurity. Long-
standing reductions in blood flow and oxygen delivery
typically lead to compensatory neovascularization.
While there are many ocular angiogenic growth factors,
a flurry of recent studies suggest that VEGF is a major
mediator of this neovascular process (Miller et al.,
1997). VEGF is an endothelial mitogen, angiogenic
protein, and a potent vasopermeability factor. VEGF is
secreted by cells and binds to endothelial fms-like ty-
rosine kinase (Flt) and kinase insert domain-containing
(KDR) receptors (Aiello, Pierce, Foley, Takagi, Chen,
Riddle, Ferrara et al., 1995).
A number of studies suggest that adenosine, by virtue
of its ability to promote VEGF formation, is a key
trigger in the growth of retinal vessels and the patho-
genesis of neovascularization. Adenosine increased
VEGF-induced proliferation of canine retinal microvas-
cular endothelial cells, a response attenuated by A2a
receptor antagonists (Lutty, Mathews, Merges &
McLeod, 1998). A series of studies in cultured bovine
retinal endothelial cells (Takagi et al., 1996a,b) revealed
the following: Prolonged hypoxia increased VEGF
binding. The adenosine A1 receptor agonist CPA had
no effect upon KDR receptor mRNA expression or
VEGF expression at low concentrations, but at higher
concentrations where it interacts with the A2 receptor,
CPA decreased KDR mRNA levels to 30% of control
and promoted VEGF expression (Fig. 6). DPMA, an
adenosine A2 receptor agonist, decreased KDR mRNA
in a dose-dependent manner while CSC, the A2a recep-
tor antagonist, attenuated the dose- and time-depen-
dent reduction in KDR gene expression by hypoxia.
The A2 agonists DPMA, NECA, and CGS21680 each
increased VEGF mRNA approximately 2-fold. Admin-
istration of adenosine deaminase reduced hypoxic ex-
pression of VEGF mRNA by 37%, while the A2a
antagonist CSC resulted in a 68% decrease. VEGF
protein increased nearly 5-fold during hypoxia in cells
exposed to NECA, an effect completely inhibited by
CSC. From these in vitro studies, it appears that the
induction of VEGF expression during hypoxia largely
results from an increase in adenosine concentration and
its binding to the A2a receptor. Although adenosine
acts to reduce the expression of the VEGF receptor
KDR via an adenosine A2 receptor-mediated effect
during acute hypoxia, prolonged hypoxia results in an
opposite effect, which may in fact parallel the clinical
manifestations of neovascularization after chronic reti-
nal ischemia.
Fig. 6. Stimulation of the adenosine A2a, but not the A1 receptor,
increases expression of VEGF. Increasing concentrations of the
adenosine A1 receptor agonist CPA or the A2a receptor agonist
CGS21680 were administered to normoxic bovine retinal pericytes in
vitro. VEGF expression was quantitated as a percent of control
(Y-axis) by Northern blot analysis. The adenosine A2a antagonist
CSC, but not the A1 antagonist DPCPX, decreased expression of
VEGF (not shown). The data are expressed as mean9S.E.M. * PB
0.05, ** PB0.01, *** PB0.001, and ‡ P0.005 versus control (i.e.,
concentration of agonist0). Redrawn with permission of the Asso-
ciation for Research in Vision and Ophthalmology from Takagi et al.
(1996b).
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In summary, adenosine participates importantly in
the neovascular response to hypoxia in the retina.
VEGF action is important in the neovascularization
response, and VEGF formation and VEGF receptors
are modulated by adenosine. An increase in adenosine
concentration, acting through its A2 receptor, results in
an increase in the expression of VEGF and a decrease
in the KDR VEGF receptor. After prolonged hypoxia,
although the number of VEGF receptors is decreased,
the binding capacity for VEGF is increased, thereby
facilitating the neovascular response.
9.4. Adenosine and retinal blood flow
Adenosine has been shown to act as a vasodilator in
heart, skeletal muscle, and brain (Phillis, 1989). A
significant role for adenosine in the regulation of retinal
blood flow in a variety of species has been forthcoming
from studies of vascular effects of exogenous adenosine,
adenosine uptake inhibitors, and adenosine receptor
antagonists. The reader is cautioned that these studies
be interpreted in view of the route of delivery of the
pharmacologic agents tested, the species studied, the
method used to estimate retinal blood flow, and the
physiologic or even pathophysiologic relevance of the
doses of agents used. Among the first studies of
adenosine’s vascular effects in the eye were those per-
formed by Braunagel, Xaio and Chiou (1988). Intravit-
real injection of adenosine or the adenosine uptake
inhibitor dipyridamole in rabbits increased retinal
blood flow as measured by laser Doppler flowmetry.
The dipyridamole-induced increase in blood flow was
caused by an increase in endogenous adenosine concen-
tration since concomitant administration of the
adenosine receptor antagonist 8-phenyltheophylline re-
turned blood flow to control levels. Using radiolabelled
microspheres, these investigators also demonstrated
that adenosine alone, dipyridamole alone, and
adenosine together with dipyridamole caused a signifi-
cant increase in blood flow to the retina, choroid, iris,
and ciliary body, again blocked by 8-phenyl-
theophylline. Comparisons of the dose-response in each
ocular tissue revealed that the retina was the most
sensitive to dipyridamole.
Similar conclusions about adenosine’s possible role in
the regulation of retinal blood flow were inferred from
intravitreal injections of extremely large doses of
adenosine and its agonists in rabbits, marmosets, and
cats (Campochiaro & Sen, 1989). In these studies,
blood flow was estimated indirectly from changes in the
diameter of large retinal veins, imaged by fundus pho-
tography 6 and 24 h after intravitreal injection.
Adenosine and dipyridamole were effective dilators
(40% increase in diameter), with dilation still present 6
h after midvitreal injection of these compounds; by 24
h, these dilatative effects subsided. Injection of a potent
adenosine receptor antagonist, BW-A1433U, reversed
this effect, confirming that adenosine was in fact re-
sponsible for the venous vasodilation. NECA, a non-
specific adenosine receptor agonist with some selectivity
for A2 adenosine receptors, caused a similar degree of
dilation, but its effect lasted for at least 24 h. Although
the vasodilatory actions of adenosine are generally
short-lived, the long-lasting effects of NECA were
likely the result of the high concentrations of NECA
injected, the slow diffusion of NECA through the vit-
reous, the tight binding of NECA to its receptor, and
the resistance of NECA to inactivation by adenosine
deaminase. The authors reported that adenosine and
dipyridamole occasionally caused small subhyaloid and
intraretinal hemorrhages in addition to vasodilation,
and concluded that adenosine might alter the integrity
of the blood-retinal barrier. In a separate study, the
same authors used vitreous fluorophotometry to mea-
sure fluorescein leakage in rabbits, and showed that the
increase in blood flow resulting from intravitreal injec-
tion of adenosine or its receptor agonists was associated
with breakdown of the blood-retinal barrier (Sen &
Campochiaro, 1989). Overall, the pathophysiologic rel-
evance of these blood flow and leakage results must be
regarded as questionable, however, because of the ex-
tremely high, non-physiological, and combined doses of
adenosine, dipyridamole, and adenosine agonists (Gid-
day & Park, 1993b).
Intravitreal microsuffusions of adenosine and several
of its receptor-specific agonists onto the retinal arterio-
lar resistance vessels of the piglet using a microscope-
guided intravitreal cannula revealed a dilation
dose-response profile consistent with adenosine actions
at A2 receptors (Gidday & Park, 1993a). Intravitreal
injections of the adenosine transport inhibitor NBTI
and the adenosine kinase inhibitor iodotubercidin both
resulted in rapid and long-lasting increases in arteriolar
diameters. The response to the former was blocked by
co-infusion of the A2 receptor antagonist DPMX.
These latter results indicated that potentiation of en-
dogenous retinal adenosine concentration by several
different pharmacologic strategies can promote vasodi-
lation and increase retinal blood flow, most likely via
an A2 receptor-mediated effect.
Although results of cerebral vascular studies are con-
sistent with adenosine action at vascular A2 adenosine
receptors positively coupled to adenylate cyclase, with
resultant formation of cAMP, studies in the piglet
retina did not support this hypothesis (Gidday et al.,
1996). Rather, we found that the adenosine-induced
hyperemia, as measured by fluorescein angiography
following intravitreal microsuffusions of adenosine, was
attenuated in a dose-dependent manner by
glibenclamide, a KATP channel antagonist. This result
indicates that KATP channels mediate adenosine’s va-
sodilatative effect. As predicted, intravitreal injection of
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cromakalim, a KATP channel opener, increased retinal
blood flow significantly, indicative of a general role for
KATP channels in the regulation of retinal blood flow.
The effect of intravascular adenosine on blood flow
in the optic nerve head, retina, and choroid was exam-
ined in cats using laser Doppler flowmetry and ve-
locimetry along with fundus photography (Portellos,
Riva, Cranstoun, Petrig & Brucker, 1995). Intravenous
infusions of adenosine increased choroidal blood flow
by 60%, but retinal and optic nerve head blood flows
were not significantly altered. It would seem that pe-
ripherally administered adenosine can leak through
choroidal capillary fenestrae and cause vasodilation of
this vascular bed, but cannot penetrate the retinal and
optic nerve blood vessels to reach what are presumably
abluminal adenosine receptors on the vascular smooth
muscle. This asymmetry was confirmed in vitro,
wherein extravascular adenosine caused dose-dependent
relaxations of isolated perfused retinal arterioles, but
equal concentrations of intravascular adenosine were
ineffective as a vasodilatory stimulus (Alder, Su, Yu,
Cringle & Yu, 1996). Thus, intravitreal administration
of adenosine and its agonists may more suitably mimic
the actual conditions under which adenosine is released
from surrounding retinal neurons than systemically ad-
ministered, intravascular adenosine.
The same conclusion might be applied to adenosine
antagonists, although the high lipophilicity of many
xanthine-based adenosine receptor antagonists will re-
sult in penetration of the blood-retinal barrier following
systemic administration, as reflected in the ability of
systemically administered caffeine to reduce the velocity
of leukocytes measured by the blue entopic technique in
humans (Lofti & Grunwald, 1991). While the results of
the latter study suggest a tonic vasodilatative role for
adenosine in the retinal microcirculation, results from
studies in both piglet (Gidday & Park, 1993b) and cat
(Ostwald et al., 1997) using intravitreal injections of
adenosine receptor antagonists do not support the con-
cept that ongoing adenosine formation contributes to
the maintenance of retinal blood flow under resting
conditions. This important hemodynamic issue will
likely have ramifications for therapies directed at the
ischemic retinal vasculature, but its resolution will re-
quire additional studies.
Results of a recent investigation suggest that
adenosine-induced increases in retinal blood flow may
occur, in part, by relaxation of retinal pericytes (Mat-
sugi, Chen & Anderson, 1997). Cultured pericytes re-
laxed in the presence of adenosine in a dose-dependent
manner. The relaxation began within 1 min of exposure
to adenosine, with a 50% effective concentration of
approximately 3107 M, similar to levels of
adenosine that would be present in the peri-vascular
spaces in vivo. The response to adenosine was re-
versible 10 min after its removal from the media. 8-
Phenyltheophylline, a nonselective adenosine receptor
antagonist, inhibited adenosine-induced pericyte relax-
ation. Since the A1-specific receptor antagonist DPCPX
had no effect on relaxation, while CP-66713, a selective
A2 receptor antagonist, inhibited adenosine-induced re-
laxation, it appears that adenosine relaxes retinal peri-
cytes by an A2 receptor-mediated mechanism.
In summary, endogenous adenosine is an important
regulator of retinal blood flow in response to changes in
substrate delivery by virtue of its ability to dilate retinal
arterioles and venules. Thus, one might predict that
these vascular effects of adenosine would be beneficial
in the setting of ischemia to promote increases in tissue
blood flow during and after a period of substrate
deprivation. This hypothesis is supported by evidence
from studies outlined below.
9.5. Blood flow and adenosine: effects of ischemia,
hypoxia, and hypoglycemia
Because adenosine is an important component of the
retinal response to oxygen and substrate deprivation,
several studies have examined its role in the regulation
of retinal blood flow under pathological conditions.
These experiments have been performed in several dif-
ferent mammalian species.
Blood flow in the retina and choroid of cats was
measured using radioactive microspheres after 60 min
of ischemia induced by elevation of intraocular pressure
(Roth & Pietrzyk, 1994). During ischemia, retinal blood
flow (RBF) was reduced to 6%, and choroidal (CoBF)
to 0.6%, of baseline. Immediately after the end of
ischemia, there were profound alterations in blood flow.
From 5 to 15 min after ischemia ended, RBF increased
to 200% of baseline and CoBF to 108% of baseline,
indicative of what is termed a reactive hyperemic re-
sponse. By 60 min, both flows had returned to nearly
baseline levels. In two subsequent experiments, the
adenosine receptor antagonist 8-SPT profoundly atten-
uated this post-ischemic hyperemia in retina but had
little effect on CoBF (Roth, 1995; Ostwald et al., 1997).
Other vasoactive substances such as nitric oxide (NO)
have since been found to play a role in this reactive
hyperemia as well. Whereas the adenosine receptor
antagonist 8-SPT alone attenuated the hyperemic re-
sponse, and nitric oxide synthase (NOS) inhibition
alone had little effect on the hyperemic response, NOS
inhibition in combination with the adenosine receptor
antagonist resulted in the reappearance of the reactive
hyperemia (Ostwald et al., 1997). The nature of this
apparent interaction between adenosine and NO is still
unclear. It is possible that NOS inhibition may have
increased retinal adenosine concentration to an extent
sufficient to overcome competitive adenosine receptor
blockade with SPT. This speculation is supported by
the findings that reactive hyperemia in the isolated
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guinea pig heart was associated with an increase in
adenosine and NO concentrations and that inhibition
of NOS by L-NAME significantly increased adenosine
release under basal and post-ischemic conditions (Kos-
tic & Schrader, 1992).
After the acute compensatory hyperemic response to
a period of retinal ischemia, retinal blood flow may fall
significantly below baseline levels in what has been
termed in cerebral ischemia a delayed hypoperfusion
response. Delayed changes in blood flow have been
documented in piglets at 1–2 h following the combina-
tion of severe hypoxia, hypotension, bradycardia, and
acidosis secondary to a short period of asphyxia (Gid-
day & Zhu, 1998), and also following periods of com-
plete ischemia (central retinal artery ligation) exceeding
30 min in the rat retina (Lin & Roth, 1998). It is
thought that this flow reduction adds additional insult
to an already ischemic tissue. Some caution is called for
in this interpretation because simultaneous measures of
retinal blood flow and metabolic rate have not yet been
undertaken to determine whether this response may
represent ongoing flow-metabolism coupling. Nonethe-
less, intravitreal administration of NBTI, an adenosine
transport inhibitor that potentiates extracellular
adenosine concentrations, completely reversed this re-
sponse in the piglet (Gidday & Zhu, 1998) (Fig. 7),
indicating that the adenosine vascular signal transduc-
tion mechanism is intact following ischemia. These
results also identify a possible therapeutic strategy to
support tissue perfusion following ischemia, namely, to
attempt to increase tissue adenosine concentration.
Retinal arterioles of the piglet dilate robustly in
response to reductions in oxygen delivery by systemic
hypoxia (PaO22591 mmHg) or to the reductions in
oxygen and glucose supply induced by systemic hy-
potension (MABP4193 mmHg). The latter re-
sponse is autoregulatory by definition. Because
intravitreal microsuffusion of 8SPT, a non-specific
adenosine receptor antagonist, significantly attenuated
each of these responses, adenosine was implicated as
responsible for mediating a large part of these re-
sponses (Gidday & Park, 1993a). Intravitreal microsuf-
fusion of NBTI to potentiate extracellular adenosine
concentrations significantly enhanced vasodilatation
during hypotension, adding further support to the hy-
pothesis that adenosine is important in mediating au-
toregulatory adjustments in retinal arteriolar tone.
As in hypoxia, the retina reacts to hypoglycemia with
a compensatory increase in blood flow (Zhu & Gidday,
1996). We used fluorescein videoangiography to mea-
sure blood flow in newborn pigs rendered hypoglycemic
by insulin injection. Acute hypoglycemia (blood glu-
cose1991 mg:dl) doubled RBF secondary to a dila-
tion of arterioles and a decrease in arteriovenous transit
time. Intravenous pretreatment with the adenosine re-
ceptor antagonist 8-phenyltheophylline significantly at-
Fig. 7. Effect of extracellular adenosine potentiation with the trans-
port inhibitor NBTI on post-asphyxic retinal blood flow in piglets.
Changes in retinal blood flow (normalized to pre-asphyxic baseline
values, mean9S.E.M.) were measured by videofluorescein angiogra-
phy at 1 and 2 h after 9 min of asphyxia in a vehicle-treated control
animal group (n6; open bars) and a group (n6; shaded bars)
treated with 0.1 nmol of NBTI administered as an intravitreal micro-
suffusion (50 ml of a 2 mM solution) over the retinal vessels under
videomicroscopic observation. Intravitreal NBTI reversed the postas-
phyxic hypoperfusion into a relative hyperemia. (* PB0.05 versus
preasphyxic baseline; † PB0.05 versus control group at same postas-
phyxic time). Reprinted with permission of Oxford Press, Inc., from
Gidday et al. (1998).
tenuated the hypoglycemia-induced retinal hyperemia,
indicating that adenosine is critical to the elicitation of
this response as well (Fig. 8). Hypoglycemia is likely to
promote increases in adenosine formation because of
limired available substrate and the consequent decrease
in ATP concentration.
In summary, adenosine formation in response to
hypoxia, hypoglycemia, and ischemia affects retinal
blood flow. Adenosine’s ability to increase blood flow
in a compensatory manner in response to either reduc-
tions in oxygen and:or glucose supply reflects its status
as an endogenous retaliatory metabolite (Perez-Pinzon,
Lutz, Sick & Rosenthal, 1993). Exogenous therapies
aimed at increasing adenosine concentration may im-
prove tissue perfusion following ischemia.
9.6. Ischemic preconditioning
Ischemic preconditioning (IPC) is an intriguing phe-
nomenon in which a state of resistance to ischemic
injury is produced by a previous, brief, non-damaging
period of ischemia. IPC was recently demonstrated to
be operative in the retina (Roth et al., 1998). Under-
standing the endogenous mechanisms by which IPC
protects the retina can give insight into possible preven-
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tive and:or treatment options for retinal ischemic
disorders.
When 5 min of ischemia (IPC) was followed 24 or 72
h later by 60 min of ischemia in rats, complete func-
tional recovery (by electroretinography) occurred
within 24 h, and no histological damage was present 7
days after ischemia, a dramatic effect that has not been
seen to any similar extent following any type of exoge-
nous pharmacological manipulation. These effects are
time-dependent; separation of the 5 min IPC stimulus
and 60 min of ischemia by either 1 or 168 h resulted in
no protection against the effects of ischemia. The pro-
tective effect of IPC was attenuated completely by
inhibition of protein synthesis.
Adenosine appears to be required for IPC-mediated
protection in this model (Li & Roth, in press). Pretreat-
ment with the adenosine A1 receptor antagonist
DPCPX prior to IPC attenuated recovery from 60 min
of ischemia in a dose-dependent manner. The adenosine
A2a receptor antagonist CSC, which is 25-fold selective
for the A2a receptor, partially attenuated the effects of
preconditioning, but only at the highest dose used (1.0
mg:kg). Intravitreal injection of adenosine receptor ag-
onists produced a partial mimicking of the IPC effect.
The pathways responsible for preconditioning protec-
tion probably involve a complex series of other as yet
incompletely described mediators.
10. Conclusions
Adenosine mediates vital changes in oxygen delivery
to the retina when blood flow and substrate delivery are
altered, as for example during hypoxia, ischemia, or
hypoglycemia. Under these conditions, adenosine ap-
pears to be one of the major mediators. Large changes
in adenosine concentration during both ischemia and
during the ensuing reperfusion period affect function,
mediated by both adenosine A1 and A2a receptors,
which can produce opposing effects. Under some cir-
cumstances, particularly after prolonged ischemia, in-
creases in adenosine concentration could be injurious,
due to the formation of superoxide radicals following
adenosine’s conversion to xanthine and uric acid.
Moreover, in vitro studies suggest that chronic ischemia
and hypoxia stimulate increases in VEGF, a mediator
of neovascularization, in an adenosine-dependent man-
ner. The induction of a remarkably tolerant state to
ischemic injury (ischemic preconditioning) is mediated
by adenosine, suggesting a novel means to further
explore the role of adenosine in ischemic protection of
the retina. Overall, these findings indicate that
adenosine is one of the major components of the reti-
na’s response to acute or chronic ischemia. As such, the
continued investigation of the involvement of adenosine
in the retina may lead to important clinical applications
of adenosine-based therapies in retinal ischemic
disorders.
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30 min of hypoglycemia (n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2091 mg:dl; ) was
significantly attenuated in animals pretreated with 8-PT 15 min before
hypoglycemia (n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1993 mg:dl; ). (* PB0.05
versus normoglycemic baseline; † PB0.05 versus control group at
same time of hypoglycemia). Reprinted with permission of the Asso-
ciation for Research in Vision and Ophthalmology, from Zhu and
Gidday (1996).
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